TFS Capital’s Theriva Biologics TOVX Stock Holding History

TFS Capital’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-6	Closed	-$159K	–	1040
2015 Q2	$159K	Sell	6 -16	-73%	-$321K	0.02%	778
2015 Q1	$427K	Buy	22 +4	+22%	+$71.4K	0.04%	596
2014 Q4	$230K	Buy	+18	New	+$242K	0.02%	791
2014 Q3	–	Sell	-23	Closed	-$345K	–	1210
2014 Q2	$345K	Sell	23 -30	-57%	-$476K	0.03%	783
2014 Q1	$1.19M	Buy	+53	New	+$1.1M	0.08%	390

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BGA

Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TFS Capital's TOVX Position: Q3 2015 in Review

TFS Capital sold out of Theriva Biologics (TOVX) in Q3 2015, closing a stake of 6 shares — an estimated $159K sold.

TFS Capital first reported a position in TOVX in Q1 2014 and held it in 5 quarters. The position peaked at $1.19M in Q1 2014. 45 funds tracked by Wall St. Rank hold TOVX as of Q3 2015.

TFS Capital reported no remaining Theriva Biologics position as of Q3 2015 after selling out during the quarter.
TFS Capital sold 6 Theriva Biologics shares in Q3 2015, an estimated $159K.
TFS Capital first reported a position in Theriva Biologics in Q1 2014 and held it in 5 quarters.
TFS Capital's Theriva Biologics position peaked at $1.19M in Q1 2014.
45 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2015.

Based on TFS Capital's 13F filing for Q3 2015, filed 3 Nov 2015.